Evaluation Heart Failure with Reduced Ejection Fraction: Guidance for Navigating an Evolving Therapeutic Landscape Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Describe the phenotypes of HF, including worsening disease, in terms of current diagnostic challenges and overall burden 5 4 3 2 1 Evaluate the safety/efficacy and mechanisms of action of key pharmacological therapies for the treatment of HFrEF 5 4 3 2 1 Recognize patients with worsening HFrEF and implement guideline - directed therapeutic strategies to decrease overall morbidity, mortality, and hospitalization rates 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). William Chavey, MD, MS 5 4 3 2 1 Alanna A. Morris, MD, MSc, FHFSA, FACC, FAHA 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients with heart failure do you see during a typical month? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No If a patient presents with dyspnea or fatigue due to left ventricular systolic dysfunction, or is asymptomatic and is undergoing treatment for prior symptoms of heart failure, which stage of heart failure is he/she in, according to the ACC/AHA? Stage A Stage B Stage C Stage D Which of the following choices best describes the LVEF phenotypes of HF? HFrEF where LVEF is less than or equal to 20%; HFmrEF where LVEF is 21-29%; HFpEF where LVEF is greater than or equal to 30% HFrEF where LVEF is less than or equal to 30%; HFmrEF where LVEF is 31-39%; HFpEF where LVEF is greater than or equal to 40% HFrEF where LVEF is less than or equal to 40%; HFmrEF where LVEF is 41-49%; HFpEF where LVEF is greater than or equal to 50% HFrEF where LVEF is less than or equal to 50%; HFmrEF where LVEF is 51-59%; HFpEF where LVEF is greater than or equal to 60% In 2021, ___________ received an expanded FDA approval to reduce the risk of CV death and hospitalization for HF in adults with HFrEF, in addition to its indications for patients with type 2 diabetes. Canagliflozin Dapagliflozin Empagliflozin Sotagliflozin According to the 2021 ESC guidelines, which of the following treatments should be administered to adults recently hospitalized or treated with outpatient IV diuretics, and is the first therapy for HF specifically for patients following HFH or with WHF? Candesartan Dapagliflozin Ivabradine Vericiguat How confident are you in your ability to implement appropriate, evidence-based strategies for the management and prevention of HFrEF and WHF? Very confident Confident Somewhat confident Not very confident Not at all confident Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often: (select all that apply) Select treatment for HF phenotypes based on patient characteristics, disease severity, comorbidities, and response to previous therapies Evaluate the safety/efficacy and mechanisms of action of key pharmacological therapies for the treatment of HFrEF Make informed recommendations for the treatment of HFrEF based on established treatment options presented by data-driven algorithms Remain apprised of developing clinical data and differing characteristics associated with current and emerging therapeutic options for the treatment of HFrEF and WHF Evaluate the safety/efficacy and potential advantages of all emerging agents for the treatment of HFrEF and WHF Other (please specify): Previous
